Analysis of factors affecting the prognosis of patients with non-small cell lung cancer after treatment with epidermal growth factor receptor tyrosine kinase inhibitors#br#
YU Miao1 CHEN Xiaoling2 ZHANG Yingdan1 LI Xiaoqi1 Ulantuya1 ZHANG Binbin1 MEN Tonglin3
1.The First Department of Oncology, Shenyang Tenth People’s Hospital, Liaoning Province, Shenyang 110045, China;
2.Department of Pathology, Shenyang Tenth People’s Hospital, Liaoning Province, Shenyang 110045, China;
3.Department of Interventional, Shenyang Tenth People’s Hospital, Liaoning Province, Shenyang 110045, China
Abstract：Objective To investigate the factors affecting the prognosis of patients with non-small cell lung cancer (NSCLC) after treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Methods A total of 161 NSCLC patients admitted to Shenyang Tenth People’s Hospital from January 2018 to September 2019 were selected, all of whom received first-line EGFR-TKIs treatment. According to their prognosis, they were divided into poor prognosis group (32 cases) and good prognosis group (129 cases). Clinical data, laboratory indicators, and imaging data of the two groups were collected and compared, and the influencing factors of prognosis of patients were analyzed by logistic regression model. Results The levels of programmed death-ligand 1 (PD-L1) and serum carcinoembryonic antigen (CEA) in the poor prognosis group were higher than those in the good prognosis group. The level of serum albumin, mean lung density ratio of expiration / inspiration (MLD E/I), change in lung volume as a percentage of total lung volume with a respiratory bipolar voxel index between -850 HU and -950 HU (VI-850/-950E-I) in poor prognosis group were lower than those in the good prognosis group, the differences were statistically significant (P ＜ 0.05). Multivariate analysis showed that PD-L1, serum CEA, and serum albumin were influential factors for the prognosis of NSCLC patients after EGFR-TKIs treatment (P ＜ 0.05). Conclusion PD-L1, serum CEA, and serum albumin are closely related to the prognosis of NSCLC patients after EGFR-TKIs treatment.
[1] Akhurst T. Staging of Non-Small-Cell Lung Cancer [J]. PET Clin，2018，13（1）：1-10.
[2] Zhang YL，Yuan JQ，Wang KF，et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer：a systematic review and meta-analysis [J]. Oncotarget，2016，7（48）：78985-78993.
[3] Su S，Dong ZY，Xie Z，et al. Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation [J]. J Thorac Oncol，2018，13（11）：1668-1675.
[4] Remon J，Steuer CE，Ramalingam SS，et al. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients [J]. Ann Oncol，2018，29（suppl 1）：i20-i27.
[5] Wu SG，Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer [J]. Mol Cancer，2018，17（1）：38.
[6] Hsu PC，Jablons DM，Yang CT，et al. Epidermal Growth Factor Receptor（EGFR）Pathway，Yes-Associated Protein（YAP）and the Regulation of Programmed Death-Ligand 1（PD-L1）in Non-Small Cell Lung Cancer（NSCLC）[J]. Int J Mol Sci，2019，20（15）：3821.
[7] Brody R，Zhang Y，Ballas M，et al. PD-L1 expression in advanced NSCLC：Insights into risk stratification and treatment selection from a systematic literature review [J]. Lung Cancer，2017，112：200-215.
[8] Dietel M，Bubendorf L，Dingemans AM，et al. Diagnostic procedures for non-small-cell lung cancer（NSCLC）：recommendations of the European Expert Group [J]. Thorax，2016，71（2）：177-184.
[9] 冯奉仪.实体瘤新的疗效评价标准（解读1.1版RECIST标准）[C]//第三届中国肿瘤内科大会教育集暨论文集，2009：141-143.
[10] Ahn MJ，Sun JM，Lee SH，et al. EGFR TKI combination with immunotherapy in non-small cell lung cancer [J]. Expert Opin Drug Saf，2017，16（4）：465-469.
[11] 黄世明，岳建兰，尹亮.EGFR-TKIs联合化疗治疗EGFR突变型非小细胞肺癌的研究进展[J].武警医学，2021， 32（3）：265-268.
[12] 邵宜，钟殿胜.基因融合介导EGFR-TKI获得性耐药[J].中国肺癌杂志，2020，23（5）：381-387.
[13] Incorvaia L，Fanale D，Badalamenti G，et al. Programmed Death Ligand 1（PD-L1）as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer（NSCLC） [J]. Adv Ther，2019， 36（10）：2600-2617.
[14] Kloten V，Lampignano R，Krahn T，et al. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC [J]. Cells，2019，8（8）：809-814.
[15] 王珊，董丽儒，任会强，等.非小细胞肺癌PD-1、PD-L1mRNA与EGFR基因突变的相关性分析[J].临床与实验病理学杂志，2018，34（10）：1091-1095.
[16] Altan M，Pelekanou V，Schalper KA，et al. B7-H3 Expression in NSCLC and Its Association with B7-H4，PD-L1 and Tumor-Infiltrating Lymphocytes [J]. Clin Cancer Res，2017，23（17）：5202-5209.
[17] 嵇晓辉，冯智坤，门颖丽，等.非小细胞肺癌中PD-L1、PD-1蛋白表达及其与EGFR基因突变的相关性研究[J].中国现代医药杂志，2020，22（2）：28-31.
[18] 邹琳，兰建云，宋曙，等.非小细胞肺癌PD-L1蛋白表达、EGFR基因突变状态及二者相关性研究[J].国际检验医学杂志，2019，40（22）：2698-2702，2707.
[19] Han JJ，Kim DW，Koh J，et al. Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer [J]. Clin Lung Cancer，2016，17（4）：263-270.e2.
[20] Kang X，Li P，Zhang C，et al. The TLR4/ERK/PD?L1 axis may contribute to NSCLC initiation [J]. Int J Oncol，2020， 57（2）：456-465.
[21] 梅馨方，吴熠.EGFR基因突变状态与非小细胞肺癌患者临床特征及血清肿瘤标志物水平关系分析[J].标记免疫分析与临床，2020，27（7）：1198-1202，1227.
[22] 谢占强.EGFR基因突变与非小细胞肺癌患者临床特征、肿瘤标志物的相关性研究[J].河南医学研究，2019， 28（11）：1960-1962.
[23] Numata T，Endo T，Yanai H，et al. Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients：Correlation With Distant Metastasis [J]. In Vivo，2020，34（4）：2095-2100.
[24] Li SQ，Jiang YH，Lin J，et al. Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals [J]. Cancer Med，2018，7（4）：1221-1231.
[25] 刘益民，贾坤林，徐翠容，等.血清白蛋白、前白蛋白水平对非小细胞肺癌患者预后的影响[J].标记免疫分析与临床，2018，25（2）：232-235.
[26] Dal Bello MG，Filiberti RA，Alama A，et al. The role of CEA，CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer（NSCLC）patients [J]. J Transl Med，2019，17（1）：74.
京公网安备 11010502046598号